Citigroup
PTHS

Citigroup’s Pelthos Therapeutics PTHS Stock Holding History

Citigroup’s Portfolio PTHS Stock Details PTHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21 Buy
+1
New +$24 ﹤0.01% 5695
2025
Q4 		– Sell
-1
Closed -$28 – 6547
2025
Q3 		$28 Buy
+1
New +$24 ﹤0.01% 5885

Other funds holding PTHS

M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
DMKJ
David M. Knott Jr $168M AUM 60.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PFCS
Pale Fire Capital SE Prague, Czech Republic $1.14B AUM 42.87% 1-Year Est. Return

Citigroup's PTHS Position: Q1 2026 in Review

Citigroup opened a new position in Pelthos Therapeutics (PTHS) in Q1 2026: 1 share worth $21. The stake represents ﹤0.01% of the portfolio and ranks #5695 among its holdings. This is a return to the name: Citigroup previously reported a position in PTHS as recently as Q3 2025.

Citigroup first reported a position in PTHS in Q3 2025 and has held it in 2 quarters since. The position peaked at $28 in Q3 2025. 17 funds tracked by Wall St. Rank hold PTHS as of Q1 2026.

  • Citigroup held 1 share of Pelthos Therapeutics worth $21 as of Q1 2026.
  • Pelthos Therapeutics was a new Citigroup position in Q1 2026.
  • Pelthos Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5695 holding.
  • Citigroup first reported a position in Pelthos Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • Citigroup's Pelthos Therapeutics position peaked at $28 in Q3 2025.
  • 17 funds tracked by Wall St. Rank held Pelthos Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.